OSE Immunotherapeutics SA (OSE) Cash €11.1M; ARTEMIA Interim Readout Slips to Early-2027
OSE Immunotherapeutics SA reported €11.1M cash as of June 30, 2026 (vs €17.0M at Mar 31) and said its bridge financing plus cash funds operations through Dec 2026. The ARTEMIA Phase 3 futility analysis is now expected early-2027 due to slower-than-expected death events.Material DetailsContext by AI…